Live Quote · NASDAQACXPHealthcare· Biotechnology

Acurx Pharmaceuticals, Inc.

$1.60 4.55%(+$0.07)
TickerSpark Score
59/100
Mixed
100
Valuation
20
Profitability
60
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACXP research report →

52-Week Range3% of range
Low
$1.33
Current
$1.60
High
$11.72
Company Overviewwww.acurxpharma.com

About the company

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme.

CEO
David Luci
IPO
2021
Employees
4
HQ
Staten Island, NY, US

Price Chart

-83.56% · this period
$10.00$5.67$1.35Jul 02Dec 31Jul 02
Valuation
Market Cap
$2.54M
P/E
-0.32
P/S
0.00
P/B
0.34
EV/EBITDA
0.90
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-153.93%
ROIC
-108.82%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-7,966,538 · 43.51%
EPS
$-5.32 · 69.76%
Op Income
$-8,091,983
FCF YoY
-65271.28%
Performance & Tape
52W High
$11.72
52W Low
$1.33
50D MA
$1.83
200D MA
$3.29
Beta
-2.04
Avg Volume
118.98K

Get TickerSpark's AI analysis on ACXP

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Apr 20, 26Sailer Carlother2,150
Apr 20, 26DEAN JACK Hother2,150
Apr 20, 26Donohue James J.other2,150
Apr 20, 26HARRISON THOMAS Lother2,150
Apr 20, 26Scodari Joseph Cother2,150
Apr 20, 26DELUCCIA ROBERT Jother37,100
Apr 20, 26LUCI DAVID Pother37,100
Apr 20, 26Shawah Robert G.other25,900
Feb 5, 25Shawah Robert G.other145,500
Feb 5, 25LUCI DAVID Pother250,000
Coverage · ACXP

Our ACXP coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ACXP yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ACXP report →
Internal Compare

Similar companies

Peers in the same neighborhood.